Literature DB >> 18535026

Relapses in multiple sclerosis are age- and time-dependent.

H Tremlett1, Y Zhao, J Joseph, V Devonshire.   

Abstract

OBJECTIVES: To examine the relative relapse-rate patterns over time in a relapsing multiple sclerosis (MS) cohort and to investigate potential predictors of relapse rates and periods of low-relapse activity.
METHODS: This retrospective cohort study followed 2477 relapsing-remitting (RR) MS patients from onset to 1 July 2003. Annualised relapse rates were examined according to sex, age at onset, the patient's current age and disease duration. The relationship between relapse rates and baseline characteristics (sex, onset age and onset symptoms) were examined using Poisson regression. Time to the first 5 years relapse-free was examined using Kaplan-Meier survival analysis.
RESULTS: The mean follow-up time (from onset of MS symptoms) was 20.6 years, during which time 11,722 post-onset relapses were recorded. The relapse rate decreased by 17% every 5 years (between years 5 to 30 post-onset), but this decline increased in magnitude with increasing onset age. Women and those with onset sensory symptoms exhibited a higher relapse rate (p< or =0.001). More than three-quarters of patients (1692/2189) experienced a 5-year relapse-free period during the RR phase.
CONCLUSION: Relapse rates were age- and time-dependent. Our observations have clinical implications: 1) any drug able to modify relapse rates has the greatest potential for a population impact in patients <40 years old and within the first few demi-decades of disease; 2) continuation of drug beyond these times may be of limited value; 3) long-term follow-up studies must consider that relapse rates probably decline at different rates over time according to the patient's onset age; 4) a relapse-quiescent period in MS is not uncommon.

Entities:  

Mesh:

Year:  2008        PMID: 18535026     DOI: 10.1136/jnnp.2008.145805

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  48 in total

1.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

Review 2.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

3.  Late-onset MS is associated with an increased rate of reaching disability milestones.

Authors:  Mads Albrecht Andersen; Mathias Due Buron; Melinda Magyari
Journal:  J Neurol       Date:  2021-03-07       Impact factor: 4.849

Review 4.  Multiple sclerosis in men: management considerations.

Authors:  Riley Bove; Allison McHenry; Kerstin Hellwig; Maria Houtchens; Neda Razaz; Penelope Smyth; Helen Tremlett; A D Sadovnick; D Rintell
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

5.  Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Mary Butler; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter
Journal:  Mult Scler       Date:  2019-07-29       Impact factor: 6.312

6.  Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Yinshan Zhao; Afsaneh Shirani; Elaine Kingwell; Charity Evans; Mia van der Kop; Joel Oger; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2014-06-17       Impact factor: 4.897

7.  A seasonal periodicity in relapses of multiple sclerosis? A single-center, population-based, preliminary study conducted in Bologna, Italy.

Authors:  Fabrizio Salvi; Ilaria Bartolomei; Michael H Smolensky; Angelo Lorusso; Elena Barbarossa; Anna Maria Malagoni; Paolo Zamboni; Roberto Manfredini
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

8.  Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Authors:  Kaarina Kowalec; Kyla A McKay; Scott B Patten; John D Fisk; Charity Evans; Helen Tremlett; Ruth Ann Marrie
Journal:  Neurology       Date:  2017-11-08       Impact factor: 9.910

9.  Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Authors:  Tobias Derfuss; Daniel Ontaneda; Jacqueline Nicholas; Xiangyi Meng; Kathleen Hawker
Journal:  Mult Scler Relat Disord       Date:  2016-05-24       Impact factor: 4.339

10.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.